1. Home
  2. CTNM vs PERI Comparison

CTNM vs PERI Comparison

Compare CTNM & PERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • PERI
  • Stock Information
  • Founded
  • CTNM 2009
  • PERI 1999
  • Country
  • CTNM United States
  • PERI Israel
  • Employees
  • CTNM N/A
  • PERI N/A
  • Industry
  • CTNM
  • PERI EDP Services
  • Sector
  • CTNM
  • PERI Technology
  • Exchange
  • CTNM Nasdaq
  • PERI Nasdaq
  • Market Cap
  • CTNM 378.7M
  • PERI 430.0M
  • IPO Year
  • CTNM 2024
  • PERI 2006
  • Fundamental
  • Price
  • CTNM $14.14
  • PERI $8.52
  • Analyst Decision
  • CTNM Strong Buy
  • PERI Hold
  • Analyst Count
  • CTNM 4
  • PERI 5
  • Target Price
  • CTNM $29.25
  • PERI $10.17
  • AVG Volume (30 Days)
  • CTNM 82.5K
  • PERI 265.9K
  • Earning Date
  • CTNM 11-06-2024
  • PERI 02-05-2025
  • Dividend Yield
  • CTNM N/A
  • PERI N/A
  • EPS Growth
  • CTNM N/A
  • PERI N/A
  • EPS
  • CTNM N/A
  • PERI 0.93
  • Revenue
  • CTNM N/A
  • PERI $602,939,000.00
  • Revenue This Year
  • CTNM N/A
  • PERI N/A
  • Revenue Next Year
  • CTNM N/A
  • PERI N/A
  • P/E Ratio
  • CTNM N/A
  • PERI $9.25
  • Revenue Growth
  • CTNM N/A
  • PERI N/A
  • 52 Week Low
  • CTNM $12.33
  • PERI $7.47
  • 52 Week High
  • CTNM $22.00
  • PERI $31.60
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • PERI 46.91
  • Support Level
  • CTNM N/A
  • PERI $8.48
  • Resistance Level
  • CTNM N/A
  • PERI $9.09
  • Average True Range (ATR)
  • CTNM 0.00
  • PERI 0.28
  • MACD
  • CTNM 0.00
  • PERI -0.06
  • Stochastic Oscillator
  • CTNM 0.00
  • PERI 18.75

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

Share on Social Networks: